Abstract 393P
Background
Pulmonary mucinous epidermoid carcinoma (PMEC) is malignant and extremely rare. With only few case reports or small case series are reported, the prognosis of PMEC is not fully understood. In this study, we aimed to evaluate the prognostic factors of PMEC and to establish a prognostic nomogram model to predict its cancer-specific survival (CSS).
Methods
Within the Surveillance, Epidemiology, and End Results (SEER) Database from its inception to December 31, 2016, patients diagnosed with PMEC were retrospectively identified. Kaplan–Meier analysis and Cox regression were performed to evaluate the CSS stratified by different covariates. A predictive model of nomograms was conducted and the Concordance index (C-index) and calibration curves were used to validate the model.
Results
A total of 585 PMEC patients are identified. The 5-, 10-, and 20-year CSS of stage I-II PMEC were 96.0%, 91.4%, and 88.9%, respectively. The 1-, 3-, 5-, and 10-year CSS of stage III-IV PMEC were 56.5%, 39.45%, 32.1%, 29.4%, respectively. The results of survival curves showed that patients with older ages, larger tumor sizes, bilateral tumors, poorer differentiation and higher stage of T, N and M aligned with poorer prognosis. Surgical treatment significantly improved the patients’ CSS (P < 0.001). But combined therapy didn't present better CSS results than surgery alone did. The multivariate COX results revealed that the covariates of age, bilateral tumor, tumor sizes, pathological differentiation grade, T stage, N stage, M stage and therapy were independent prognosis factors for PMEC. These factors were used to construct a nomogram. The C-index of the nomogram was 0.921. The calibration curve showed that favorable consistency between the predicted PMEC CSS and the actual observation. Validation of the nomogram was conducted with the validation cohort. The C-index of validation was 0.968, and the calibration curve showed favorable consistency.
Conclusions
Age, bilateral tumor, tumor sizes, pathological differentiation grade, T stage, N stage, M stage, and therapy were independent prognosis factors of PMEC patients. A nomogram on predicting the CSS of PMEC was first built and validated, showing its potential value in practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Lingxiao Qiu.
Funding
The National Natural Science Foundation of China (No.81874042).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
223P - Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)
Presenter: Karim Fizazi
Session: e-Poster Display Session
224P - Associations of pre-existing cardiovascular disease (CVD) with treatment patterns and survival outcomes in patients with localized prostate cancer: A real-world, population-based study
Presenter: Atul Batra
Session: e-Poster Display Session
225P - Prostate cancer treatments and outcomes in the elderly: A retrospective analysis of an Australian real-world cohort
Presenter: Michael Fernando
Session: e-Poster Display Session
226P - Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Andrew Jensen
Session: e-Poster Display Session
227P - Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199
Presenter: Ulka Vaishampayan
Session: e-Poster Display Session
228P - Symptoms and impacts of metastatic castration-resistant prostate cancer (mCRPC) among Japanese patients designated to receive Ra-223
Presenter: Hiroji Uemura
Session: e-Poster Display Session
229P - Expanding the role of supervised exercise on fatigue in prostate cancer patient receiving androgen deprivation therapy: A meta-analysis of randomized controlled trial
Presenter: Niwanda Yogiswara
Session: e-Poster Display Session
230P - Molecular profiling and clinical characteristics of Chinese patients with prostate cancer
Presenter: Ranlu Liu
Session: e-Poster Display Session
231P - Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) 1-3 from KEYNOTE-199
Presenter: Jeffrey Goh
Session: e-Poster Display Session
232P - Real-world data on metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: A regional experience
Presenter: Rachel Raju
Session: e-Poster Display Session